Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Announced in June 2025, the CNPV program aims to expedite the review of drugs that address unmet medical needs, improve affordability, or support public health priorities
That observation points to a potential inflection in access and affordability that could distinguish Foundayo from semaglutide-based options in the years ahead
Because retatrutide does not hold a marketing authorisation in the UK, it is unlawful to sell, supply, or advertise it as a medicinal product under the Human Medicines Regulations 2012 (HMR 2012)
All of this is trial data, not a safety guarantee
B.ElbrondB.RolanP.ZdravkovicM
They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose
